It appears that Tesla is on the verge of acquiring SolarCity Corporation after the FTC announced its approval of the $2.6 billion deal late last week. The FTC’s approval of the deal came earlier than many expected, as the deal obtained early termination from the FTC. The deal between Tesla and SolarCity was finalized only […]
The FTC was a recently dealt a significant blow in the context of a healthcare merger. Early last week, a Pennsylvania federal judge denied the FTC’s request to block the proposed healthcare merger between Penn State Hershey Medical Center and PinnacleHealth System, even over concerns raised by the FTC that the proposed merger “would substantially […]
In late December 2015, the FTC authorized an action to block a proposed merger between Advocate Health Care Network and NorthShore University HealthSystem; two of the foremost providers of general acute inpatient hospital services in the North Shore area of Chicago, Illinois. Proposed Merger Would Create Largest Hospital System in North Shore Area The FTC’s […]
A routine part of FTC enforcement actions in federal court is the FTC’s use of witness declarations, which operate much the same as affidavits. Pursuant to 28 U.S.C. § 1746 a party may submit an unsworn declaration in lieu of a sworn affidavit. A declaration, unlike an affidavit that is made under oath before a […]
U.S. District Court judge ruled in favor of the FTC in it’s attempt to stop the proposed merger between Sysco and US Foods. The merger is done.
The FTC has moved to challenge the proposed merger between Mentor, Steris Corp. and Synergy Health, which would see Steris acquire Synergy.
The FTC has announced that it has approved a $27.4 billion merger between cigarette barons Reynolds American Inc. and Lorillard Inc.
ProMedica Health System, Inc.’s bid to buy St. Luke’s Hospital has been dealt the final knockout blow by the U.S. Supreme Court.
H.J. Heinz and Kraft Foods Group Inc. recently announced a proposed merger between the two food giants. The deal is valued at approximately $45 billion.
Novartis AG has won the FTC’s approval to buy GlaxoSmithKline’s (“GSK”) oncology drugs, but with certain conditions.